Nanoscope Therapeutics Inc., a Dallas-based clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, has appointed Jean Chang, as vice president of clinical operations and Victor Adeniyi as Senior Director of CMC.
Their appointments expand Nanoscope’s clinical and chemistry, manufacturing, and controls (CMC) team, the company said in a statement.
“As we make steady progress with our clinical trials, their expertise will help support the continued advancement of our optogenetic gene therapies to restore vision in millions of people blinded by retinal diseases,” CEO Sulagna Bhattacharya said in a statement.
The company also recently announced a new gene therapy manufacturing partnership with contract research organization Charles River Laboratories International.
Adding experts in managing clinical trials, manufacturing
Chang brings more than 20 years of experience in clinical operations and project management resulting in successful clinical trials in various therapeutic areas including CNS, cardiorenal, hematology, oncology, and ophthalmology, Nanoscope said. Previously, Chang was executive director of clinical operations at Catalyst Biosciences, and senior director, clinical operations at Adverum Biotechnologies.
Adeniyi has a decade of experience in cGMP manufacturing of biologics, including cell and gene therapy, leading successful manufacturing of clinical trial materials, Nanoscope said. He previously was head of manufacturing and tech transfer at UT Southwestern Medical Center in Dallas and manufacturing expert at Novartis Pharmaceuticals. Adeniyi also has extensive experience in cGMP manufacturing while leading teams at Lonza, and Fujifilm Diosynth Biotechnologies.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.